Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 2015 Jan;21(1):4-7
Date
10/04/2014Pubmed ID
25278457Pubmed Central ID
PMC4272893DOI
10.1016/j.bbmt.2014.09.017Scopus ID
2-s2.0-84924246712 (requires institutional sign-in at Scopus site) 75 CitationsAbstract
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) conducts large, multi-institutional clinical trials with the goal of improving the outcomes of hematopoietic cell transplantation (HCT) for patients with life-threatening disorders. Well-designed HCT trials benefit from standardized criteria for defining diagnoses, treatment plans, and graft source selection. In this perspective, we summarize evidence supporting criteria for the selection of related and unrelated adult volunteer progenitor cell donors or umbilical cord blood units. These standardized criteria for graft source selection have been adopted by the BMT CTN to enhance the interpretation of clinical findings within and among future clinical protocols.
Author List
Howard CA, Fernandez-Vina MA, Appelbaum FR, Confer DL, Devine SM, Horowitz MM, Mendizabal A, Laport GG, Pasquini MC, Spellman SRAuthors
Mary M. Horowitz MD, MS Professor in the Medicine department at Medical College of WisconsinMarcelo C. Pasquini MD, MS Professor in the Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Bone Marrow TransplantationClinical Trials as Topic
Consensus
Cord Blood Stem Cell Transplantation
HLA Antigens
Hematopoietic Stem Cell Transplantation
Histocompatibility Testing
Humans
Tissue Donors
Transplantation, Homologous
